Stem-cell specialist ReNeuron (RENE) has filed an Investigational New Drug (IND) application with the US Food and Drug Administration (FDA) to start clinical trials for its new retinitis pigmentosa (RP) product. Retinitis Pigmentosa is a group of hereditary eye diseases which lead to loss of sight as cells in the retina become damaged and eventually die. The proposed trial will take place at Massachusetts Eye and Ear clinical centre, Boston, a world-renowned institution for the treatment of retinal diseases.
IC TIP:
Buy
at
3.6p
